Science Corporation’s PRIMA chip gives first Stargardt patient a new sight test

Science Corporation has implanted its vision-restoring PRIMA chip in its first patient with Stargardt disease, marking an early clinical milestone for a device the company says could help people with otherwise untreatable sight loss regain useful central vision. The first patient received the implant in Australia in May, and during rehabilitation was able to identify a letter and later read a word, according to CEO Max Hodak.

The development matters because Stargardt disease is a progressive inherited retinal disorder that typically erodes sharp central vision and has no cure. If PRIMA continues to perform in trials, it could become one of the clearest examples yet of how brain-computer interface-style technology might move beyond experimental neuroscience and into practical medical care.

Hodak, who previously co-founded Neuralink and later left to start Science Corporation, said the company views retinal prostheses, cochlear implants and similar systems as part of a broader family of brain-computer interfaces. In his view, the technology is not only about controlling devices with thought, but also about restoring lost sensory and neurological function.

What Science Corporation announced

Science Corporation said its PRIMA implant has now been placed in a patient with Stargardt disease, an inherited condition that gradually destroys the cells needed for central sight. The company disclosed the milestone during TechCrunch Disrupt, where Hodak described how the device fits into his larger plan for building medical BCIs with real-world use cases.

The company did not frame the implant as a finished cure. Instead, it presented the result as a promising trial step in a multi-stage effort to restore vision in patients whose photoreceptors have degenerated but whose remaining retinal circuitry may still be usable.

PRIMA is already available commercially in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration. Science believes the same basic approach can be adapted to other diseases that damage the outer retina, including Stargardt disease, which affects a younger population and is widely considered incurable today.

Hodak argued that the retina should be thought of as part of the central nervous system and grouped retinal prostheses with other forms of brain-computer interfaces, including cochlear and motor implants.

How does the PRIMA implant work?

PRIMA works by replacing some of the function of damaged photoreceptors with a tiny chip and a pair of camera-equipped glasses. Patients first undergo a surgical procedure in which the implant is positioned at the back of the eye, where light-sensing cells have already died. The glasses capture the scene in front of the wearer and send that visual information to the implant, which then stimulates remaining retinal tissue.

In effect, the system acts like an artificial photoreceptor layer. The goal is not to restore normal eyesight all at once, but to return a usable patch of central vision that may allow patients to read letters, recognize patterns or perform other close-up tasks more easily.

What makes the device different from ordinary vision aids?

Unlike glasses or magnifiers that simply enlarge what the eye can already detect, PRIMA is designed to create a new signal pathway where the natural one has failed. That makes it closer to a sensory prosthesis than a conventional low-vision aid.

Hodak described the implant as a very small device placed in the back of the eye, saying the field of view is limited and the image is black and white, but sharp enough to distinguish a few letters at a time. He compared the experience to looking through a narrow tube rather than seeing a full scene.

The company’s near-term challenge is to expand that field of view while also improving resolution. That means designing a larger implant that can fit the eye’s curvature and shrinking the electrodes so they can reproduce finer detail.

Why Stargardt disease is such a difficult target

Stargardt disease is difficult because it attacks central vision, the part of sight people rely on for reading, faces and detailed work. The disease gradually kills the light-sensing cells in the outer retina, creating a growing blind spot in the center of a patient’s visual field.

Importantly, some of the inner retinal circuitry can remain intact even after photoreceptors die. That is the opening Science Corporation is trying to exploit. If the remaining pathway from retina to brain still functions, an external system may be able to feed it useful visual signals.

The condition affects an estimated 150,000 people worldwide who have already lost vision because of it. For those patients, existing treatments are limited, which is why even modest improvements in reading ability or object recognition can be meaningful.

Why does the company think this could work?

Science’s bet is that vision is ultimately an electrical code the brain can interpret, even if the original biology is damaged. Hodak said that if the optic nerve and connected brain regions receive the right signal, the brain can still process visual information.

That idea underpins much of modern neural engineering: rather than replacing the entire organ, the technology attempts to bridge damaged circuitry with engineered input. In the eye, that means using a prosthesis to compensate for the loss of photoreceptors while preserving the rest of the visual pathway.

What the first patient experienced

Science Corporation said the first Stargardt patient received the implant at Sydney Eye Hospital in Australia as part of the company’s clinical trial. During the first rehabilitation session after surgery, the patient reportedly saw a letter. In the second session, the patient was able to read a word.

Those early outcomes are small by everyday standards, but they matter in the context of severe central vision loss. For a person who has lost the ability to make out printed characters, even limited letter recognition can be a major functional gain and a sign that the system is transmitting usable information.

It is still early. The trial will need to show whether those initial gains are reproducible, whether training improves performance over time and whether more patients can achieve similar or better results. Long-term durability, safety and usability will be crucial before the device can be considered broadly transformative.

How does this fit into Hodak’s larger BCI strategy?

Science Corporation was founded in 2021 after Hodak’s departure from Neuralink, with a goal of building advanced neurotechnology while first proving commercial and clinical value in medical settings. Vision restoration is that proving ground.

The company has previously said its broader BCI approach differs from Neuralink’s. Rather than placing electrodes directly into brain tissue, Science has described a sensor concept that would sit inside the skull and rest on top of the brain. That architecture is intended for a different set of neurological applications.

What kinds of conditions could follow vision restoration?

Science has signaled interest in neurological disease, stroke and other conditions where the brain’s signals are disrupted or portions of tissue are lost. Hodak said the company’s first undisclosed clinical indication will involve a neurodegenerative disease that is already well known to the public.

He also suggested that stroke recovery could eventually be addressed by connecting engineered pathways between surviving regions of the brain. In that scenario, a device would not just monitor activity, but could potentially help add new functional circuits where natural ones have been destroyed.

Hodak said the company’s long-range goal is to better understand how the brain generates the mind and, eventually, to engineer brain-like systems as a result of that research.

Where the technology could go next

Science says a next-generation version of the PRIMA system is already in development and could move into human testing within about a year. Hodak said he expects steady progress over the next five years toward much sharper vision, possibly approaching near-native acuity.

That is an ambitious claim, and one that will be watched carefully by clinicians, regulators and competing neurotechnology firms. The path from first-in-human results to widely adopted treatment is long, particularly for implantable devices that must prove not only effectiveness but also reliability across different patients and disease stages.

Still, the combination of a real patient milestone, an existing European commercial pathway and a plausible clinical use case gives Science Corporation a more concrete medical story than many early-stage BCI companies can claim. The company is not pitching a futuristic demo; it is attempting to build a reimbursable, scalable therapy around a disabling eye disease.

Why this matters beyond one patient

This milestone matters because it suggests that the BCI market may not be defined only by brain chips for communication or computer control. Medical BCIs could become a much broader category, covering vision, hearing, movement and eventually neurological monitoring or repair.

If PRIMA can show consistent benefit in Stargardt disease, it may strengthen the case for retinal prostheses as a legitimate treatment class rather than a niche research project. It would also support the idea that some forms of lost function can be restored by interfacing directly with surviving neural tissue, even when the original sensory cells are gone.

For patients with progressive vision loss, the significance is even more immediate. In conditions like Stargardt disease, every step that preserves reading ability, identifies faces or reduces dependence on assistance can change daily life in ways that are difficult to capture in a press announcement.

Key milestones in the PRIMA program

Below is a simplified timeline of the program’s public progress so far.

What experts and investors will watch next

The most important questions now are practical rather than conceptual. Can the device deliver repeatable gains across more patients? Can the field of view widen enough to make the system genuinely useful? Can the company build a business model that sustains expensive clinical development?

Regulators will also care about whether the implanted hardware is safe over time and whether the camera-glasses system is comfortable enough for daily use. For an assistive medical device, patient adoption often depends on how much training is required and how quickly the benefit appears in ordinary life.

Science Corporation has yet to prove that the PRIMA implant can become a standard treatment for Stargardt disease. But the first implantation is a concrete sign that the company has moved beyond theory and into the far more demanding environment of human clinical testing.

What happens now?

The next phase will likely focus on continued rehabilitation, additional trial participants and measurement of visual outcomes over time. Researchers will want to know whether the patient’s early ability to see a letter and read a word leads to broader gains in reading speed, accuracy and functional independence.

For Science Corporation, success would mean more than one encouraging case. It would mean validating a platform that could be adapted to multiple diseases and perhaps eventually to other parts of the nervous system. That larger ambition is what makes the PRIMA result notable: it is both a medical story and a test of a much broader theory about how engineered neural interfaces can restore function.